- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02676089
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) (TRIGGER)
A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 200/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) ALONE OR ON TOP OF OPEN-LABEL TIOTROPIUM 2.5 µg RESPIMAT® IN PATIENTS WITH ASTHMA UNCONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Caba, Argentina
- Chiesi Clinical Trial Site 432704
-
Ciudad Autónoma de Buenos Aires, Argentina
- Chiesi Clinical Trial Site 432702
-
Mar Del Plata, Argentina
- Chiesi Clinical Trial Site 432705
-
Quilmes, Argentina
- Chiesi Clinical Trial Site 432701
-
San Miguel de Tucumán, Argentina
- Chiesi Clinical Trial Site 432703
-
Tucuman, Argentina
- Chiesi Clinical Trial Site 432706
-
-
-
-
-
Gomel, Belarus
- Chiesi Clinical Trial Site 112703
-
Gomel, Belarus
- Chiesi Clinical Trial Site 112704
-
Minsk, Belarus
- Chiesi Clinical Trial Site 112701
-
Minsk, Belarus
- Chiesi Clinical Trial Site 112702
-
Minsk, Belarus
- Chiesi Clinical Trial Site 112705
-
-
-
-
-
Blagoevgrad, Bulgaria
- Chiesi Clinical Trial Site 100707
-
Burgas, Bulgaria
- Chiesi Clinical Trial Site 100720
-
Gabrovo, Bulgaria
- Chiesi Clinical Trial Site 100718
-
Haskovo, Bulgaria
- Chiesi Clinical Trial Site 100713
-
Montana, Bulgaria
- Chiesi Clinical Trial Site 100722
-
Pleven, Bulgaria
- Chiesi Clinical Trial Site 100702
-
Plovdiv, Bulgaria
- Chiesi Clinical Trial Site 100705
-
Plovdiv, Bulgaria
- Chiesi Clinical Trial Site 100708
-
Plovdiv, Bulgaria
- Chiesi Clinical Trial Site 100715
-
Ruse, Bulgaria
- Chiesi Clinical Trial Site 100716
-
Sofia, Bulgaria
- Chiesi Clinical Trial Site 100701
-
Sofia, Bulgaria
- Chiesi Clinical Trial Site 100703
-
Sofia, Bulgaria
- Chiesi Clinical Trial Site 100704
-
Sofia, Bulgaria
- Chiesi Clinical Trial Site 100709
-
Sofia, Bulgaria
- Chiesi Clinical Trial Site 100719
-
Stara Zagora, Bulgaria
- Chiesi Clinical Trial Site 100706
-
Stara Zagora, Bulgaria
- Chiesi Clinical Trial Site 100712
-
Varna, Bulgaria
- Chiesi Clinical Trial Site 100710
-
Vidin, Bulgaria
- Chiesi Clinical Trial Site 100711
-
Vidin, Bulgaria
- Chiesi Clinical Trial Site 100721
-
-
-
-
-
Blansko, Czechia
- Chiesi Clinical Trial Site 203711
-
Brandýs Nad Labem, Czechia
- Chiesi Clinical Trial Site 203702
-
Brno, Czechia
- Chiesi Clinical Trial Site 203708
-
Jindřichův Hradec, Czechia
- Chiesi Clinical Trial Site 203707
-
Kralupy Nad Vltavou, Czechia
- Chiesi Clinical Trial Site 203705
-
Moravský Krumlov, Czechia
- Chiesi Clinical Trial Site 203709
-
Opava, Czechia
- Chiesi Clinical Trial Site 203704
-
Praha, Czechia
- Chiesi Clinical Trial Site 203701
-
Praha, Czechia
- Chiesi Clinical Trial Site 203703
-
Praha, Czechia
- Chiesi Clinical Trial Site 203710
-
Rokycany, Czechia
- Chiesi Clinical Trial Site 203713
-
Teplice, Czechia
- Chiesi Clinical Trial Site 203706
-
Varnsdorf, Czechia
- Chiesi Clinical Trial Site 203712
-
-
-
-
-
Berlin, Germany
- Chiesi Clinical Trial Site 276709
-
Berlin, Germany
- Chiesi Clinical Trial Site 276712
-
Bonn, Germany
- Chiesi Clinical Trial Site 276711
-
Frankfurt am Main, Germany
- Chiesi Clinical Trial Site 276707
-
Frankfurt am Main, Germany
- Chiesi Clinical Trial Site 276714
-
Hamburg, Germany
- Chiesi Clinical Trial Site 276705
-
Hannover, Germany
- Chiesi Clinical Trial Site 276703
-
Koblenz, Germany
- Chiesi Clinical Trial Site 276708
-
Leipzig, Germany
- Chiesi Clinical Trial Site 276702
-
Leipzig, Germany
- Chiesi Clinical Trial Site 276704
-
Leipzig, Germany
- Chiesi Clinical Trial Site 276710
-
Mainz, Germany
- Chiesi Clinical Trial Site 276715
-
München, Germany
- Chiesi Clinical Trial Site 276701
-
Münster, Germany
- Chiesi Clinical Trial Site 276713
-
Rosenheim, Germany
- Chiesi Clinical Trial Site 276716
-
-
-
-
-
Balassagyarmat, Hungary
- Chiesi Clinical Trial Site 348707
-
Budapest, Hungary
- Chiesi Clinical Trial Site 348715
-
Debrecen, Hungary
- Chiesi Clinical Trial Site 348721
-
Gödöllő, Hungary
- Chiesi Clinical Trial Site 348712
-
Hatvan, Hungary
- Chiesi Clinical Trial Site 348718
-
Komárom, Hungary
- Chiesi Clinical Trial Site 348717
-
Létavértes, Hungary
- Chiesi Clinical Trial Site 348709
-
Monor, Hungary
- Chiesi Clinical Trial Site 348703
-
Mórahalom, Hungary
- Chiesi Clinical Trial Site 348719
-
Nyíregyháza, Hungary
- Chiesi Clinical Trial Site 348704
-
Nyíregyháza, Hungary
- Chiesi Clinical Trial Site 348714
-
Pécs, Hungary
- Chiesi Clinical Trial Site 348713
-
Siófok, Hungary
- Chiesi Clinical Trial Site 348702
-
Szarvas, Hungary
- Chiesi Clinical Trial Site 348706
-
Szeged, Hungary
- Chiesi Clinical Trial Site 348701
-
Szentgotthárd, Hungary
- Chiesi Clinical Trial Site 348705
-
Vecsés, Hungary
- Chiesi Clinical Trial Site 348720
-
Vásárosnamény, Hungary
- Chiesi Clinical Trial Site 348710
-
Érd, Hungary
- Chiesi Clinical Trial Site 348708
-
-
-
-
-
Bologna, Italy
- Chiesi Clinical Trial Site 380704
-
Catania, Italy
- Chiesi Clinical Trial Site 380703
-
Genova, Italy
- Chiesi Clinical Trial Site 380701
-
Palermo, Italy
- Chiesi Clinical Trial Site 380705
-
Pavia, Italy
- Chiesi Clinical Trial Site 380702
-
Tradate, Italy
- Chiesi Clinical Trial Site 380706
-
-
-
-
-
Vilnius, Lithuania
- Chiesi Clinical Trial Site 440702
-
Vilnius, Lithuania
- Chiesi Clinical Trial Site 440703
-
Vilnius, Lithuania
- Chiesi Clinical Trial Site 440705
-
Šiauliai, Lithuania
- Chiesi Clinical Trial Site 440701
-
-
-
-
-
Białystok, Poland
- Chiesi Clinical Trial Site 616713
-
Białystok, Poland
- Chiesi Clinical Trial Site 616718
-
Bielsko-Biala, Poland
- Chiesi Clinical Trial Site 616722
-
Bienkówka, Poland
- Chiesi Clinical Trial Site 616702
-
Bydgoszcz, Poland
- Chiesi Clinical Trial Site 616727
-
Gdańsk, Poland
- Chiesi Clinical Trial Site 616701
-
Giżycko, Poland
- Chiesi Clinical Trial Site 616704
-
Grudziądz, Poland
- Chiesi Clinical Trial Site 616716
-
Katowice, Poland
- Chiesi Clinical Trial Site 616725
-
Katowice, Poland
- Chiesi Clinical Trial Site 616729
-
Kraków, Poland
- Chiesi Clinical Trial Site 616719
-
Kraków, Poland
- Chiesi Clinical Trial Site 616734
-
Kraków, Poland
- Chiesi Clinical Trial Site 616736
-
Mrozy, Poland
- Chiesi Clinical Trial Site 616733
-
Ostróda, Poland
- Chiesi Clinical Trial Site 616717
-
Otwock, Poland
- Chiesi Clinical Trial Site 616731
-
Pabianice, Poland
- Chiesi Clinical Trial Site 616703
-
Poznań, Poland
- Chiesi Clinical Trial Site 616709
-
Poznań, Poland
- Chiesi Clinical Trial Site 616728
-
Proszowice, Poland
- Chiesi Clinical Trial Site 616720
-
Rzeszów, Poland
- Chiesi Clinical Trial Site 616723
-
Rzeszów, Poland
- Chiesi Clinical Trial Site 616735
-
Skierniewice, Poland
- Chiesi Clinical Trial Site 616721
-
Strzelce Opolskie, Poland
- Chiesi Clinical Trial Site 616732
-
Tarnów, Poland
- Chiesi Clinical Trial Site 616710
-
Wilkowice, Poland
- Chiesi Clinical Trial Site 616730
-
Wrocław, Poland
- Chiesi Clinical Trial Site 616705
-
Wrocław, Poland
- Chiesi Clinical Trial Site 616714
-
Wrocław, Poland
- Chiesi Clinical Trial Site 616715
-
Łódź, Poland
- Chiesi Clinical Trial Site 616707
-
Łódź, Poland
- Chiesi Clinical Trial Site 616708
-
Łódź, Poland
- Chiesi Clinical Trial Site 616711
-
Łódź, Poland
- Chiesi Clinical Trial Site 616726
-
Świdnik, Poland
- Chiesi Clinical Trial Site 616712
-
-
-
-
-
Aveiro, Portugal
- Chiesi Clinical Trial Site 620704
-
Figueira Da Foz, Portugal
- Chiesi Clinical Trial Site 620703
-
Lisboa, Portugal
- Chiesi Clinical Trial Site 620702
-
Loures, Portugal
- Chiesi Clinical Trial Site 620708
-
Vila Nova De Gaia, Portugal
- Chiesi Clinical Trial Site 620707
-
-
-
-
-
Alexandru cel Bun, Romania
- Chiesi Clinical Trial Site 642715
-
Arad, Romania
- Chiesi Clinical Trial Site 642713
-
Bacău, Romania
- Chiesi Clinical Trial Site 642722
-
Bragadiru, Romania
- Chiesi Clinical Trial Site 642717
-
Braşov, Romania
- Chiesi Clinical Trial Site 642706
-
Bucuresti, Romania
- Chiesi Clinical Trial Site 642703
-
Bucuresti, Romania
- Chiesi Clinical Trial Site 642707
-
Bucuresti, Romania
- Chiesi Clinical Trial Site 642708
-
Bucuresti, Romania
- Chiesi Clinical Trial Site 642719
-
Bucuresti, Romania
- Chiesi Clinical Trial Site 642723
-
Cluj-Napoca, Romania
- Chiesi Clinical Trial Site 642709
-
Cluj-Napoca, Romania
- Chiesi Clinical Trial Site 642714
-
Cluj-Napoca, Romania
- Chiesi Clinical Trial Site 642716
-
Cluj-Napoca, Romania
- Chiesi Clinical Trial Site 642718
-
Cluj-Napoca, Romania
- Chiesi Clinical Trial Site 642726
-
Craiova, Romania
- Chiesi Clinical Trial Site 642712
-
Iaşi, Romania
- Chiesi Clinical Trial Site 642704
-
Iaşi, Romania
- Chiesi Clinical Trial Site 642710
-
Oradea, Romania
- Chiesi Clinical Trial Site 642705
-
Suceava, Romania
- Chiesi Clinical Trial Site 642711
-
Timişoara, Romania
- Chiesi Clinical Trial Site 642721
-
-
-
-
-
Anton, Russian Federation
- Chiesi Clinical Trial Site 643724
-
Chelyabinsk, Russian Federation
- Chiesi Clinical Trial Site 643727
-
Chelyabinsk, Russian Federation
- Chiesi Clinical Trial Site 643733
-
Chelyabinsk, Russian Federation
- Chiesi Clinical Trial Site 643745
-
Izhevsk, Russian Federation
- Chiesi Clinical Trial Site 643754
-
Kazan, Russian Federation
- Chiesi Clinical Trial Site 643713
-
Kazan, Russian Federation
- Chiesi Clinical Trial Site 643719
-
Kazan, Russian Federation
- Chiesi Clinical Trial Site 643741
-
Kazan, Russian Federation
- Chiesi Clinical Trial Site 643746
-
Kemerovo, Russian Federation
- Chiesi Clinical Trial Site 643704
-
Kemerovo, Russian Federation
- Chiesi Clinical Trial Site 643731
-
Moscow, Russian Federation
- Chiesi Clinical Trial Site 643702
-
Moscow, Russian Federation
- Chiesi Clinical Trial Site 643705
-
Moscow, Russian Federation
- Chiesi Clinical Trial Site 643706
-
Moscow, Russian Federation
- Chiesi Clinical Trial Site 643718
-
Moscow, Russian Federation
- Chiesi Clinical Trial Site 643722
-
Moscow, Russian Federation
- Chiesi Clinical Trial Site 643735
-
Moscow, Russian Federation
- Chiesi Clinical Trial Site 643743
-
Nizhny Novgorod, Russian Federation
- Chiesi Clinical Trial Site 643707
-
Nizhny Novgorod, Russian Federation
- Chiesi Clinical Trial Site 643723
-
Nizhny Novgorod, Russian Federation
- Chiesi Clinical Trial Site 643744
-
Novosibirsk, Russian Federation
- Chiesi Clinical Trial Site 643717
-
Orenburg, Russian Federation
- Chiesi Clinical Trial Site 643729
-
Pyatigorsk, Russian Federation
- Chiesi Clinical Trial Site 643711
-
Ryazan, Russian Federation
- Chiesi Clinical Trial Site 643701
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643712
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643714
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643715
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643716
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643725
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643730
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643732
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643737
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643739
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643752
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643757
-
Saint Petersburg, Russian Federation
- Chiesi Clinical Trial Site 643758
-
Saratov, Russian Federation
- Chiesi Clinical Trial Site 643703
-
Saratov, Russian Federation
- Chiesi Clinical Trial Site 643736
-
Smolensk, Russian Federation
- Chiesi Clinical Trial Site 643726
-
Stavropol', Russian Federation
- Chiesi Clinical Trial Site 643740
-
Tomsk, Russian Federation
- Chiesi Clinical Trial Site 643709
-
Tomsk, Russian Federation
- Chiesi Clinical Trial Site 643728
-
Tomsk, Russian Federation
- Chiesi Clinical Trial Site 643759
-
Ufa, Russian Federation
- Chiesi Clinical Trial Site 643755
-
Vladikavkaz, Russian Federation
- Chiesi Clinical Trial Site 643708
-
Vladimir, Russian Federation
- Chiesi Clinical Trial Site 643738
-
Voronezh, Russian Federation
- Chiesi Clinical Trial Site 643710
-
Yaroslavl, Russian Federation
- Chiesi Clinical Trial Site 643720
-
Yaroslavl, Russian Federation
- Chiesi Clinical Trial Site 643734
-
Yaroslavl, Russian Federation
- Chiesi Clinical Trial Site 643742
-
Yaroslavl, Russian Federation
- Chiesi Clinical Trial Site 643749
-
Yekaterinburg, Russian Federation
- Chiesi Clinical Trial Site 643721
-
-
-
-
-
Bratislava, Slovakia
- Chiesi Clinical Trial Site 703704
-
Bratislava, Slovakia
- Chiesi Clinical Trial Site 703707
-
Ilava, Slovakia
- Chiesi Clinical Trial Site 703702
-
Košice, Slovakia
- Chiesi Clinical Trial Site 703705
-
Košice, Slovakia
- Chiesi Clinical Trial Site 703706
-
Nove Zamky, Slovakia
- Chiesi Clinical Trial Site 703701
-
Prievidza, Slovakia
- Chiesi Clinical Trial Site 703709
-
Spišská Nová Ves, Slovakia
- Chiesi Clinical Trial Site 703703
-
Štúrovo, Slovakia
- Chiesi Clinical Trial Site 703708
-
-
-
-
-
Badajoz, Spain
- Chiesi Clinical Trial Site 724703
-
Badalona, Spain
- Chiesi Clinical Trial Site 724706
-
Coruña, Spain
- Chiesi Clinical Trial Site 724702
-
Madrid, Spain
- Chiesi Clinical Trial Site 724701
-
Madrid, Spain
- Chiesi Clinical Trial Site 724704
-
Málaga, Spain
- Chiesi Clinical Trial Site 724705
-
Sabadell, Spain
- Chiesi Clinical Trial Site 724707
-
-
-
-
-
Ankara, Turkey
- Chiesi Clinical Trial Site 792701
-
Ankara, Turkey
- Chiesi Clinical Trial Site 792702
-
Antalya, Turkey
- Chiesi Clinical Trial Site 792703
-
Aydın, Turkey
- Chiesi Clinical Trial Site 792710
-
Istanbul, Turkey
- Chiesi Clinical Trial Site 792707
-
Kocaeli, Turkey
- Chiesi Clinical Trial Site 792706
-
Maltepe, Turkey
- Chiesi Clinical Trial Site 792705
-
Mersin, Turkey
- Chiesi Clinical Trial Site 792708
-
Yenişehir, Turkey
- Chiesi Clinical Trial Site 792709
-
-
-
-
-
Dnipropetrovs'k, Ukraine
- Chiesi Clinical Trial Site 804701
-
Ivano-Frankivs'k, Ukraine
- Chiesi Clinical Trial Site 804711
-
Kharkiv, Ukraine
- Chiesi Clinical Trial Site 804709
-
Kherson, Ukraine
- Chiesi Clinical Trial Site 804710
-
Kiev, Ukraine
- Chiesi Clinical Trial Site 804713
-
Kyiv, Ukraine
- Chiesi Clinical Trial Site 804705
-
Lviv, Ukraine
- Chiesi Clinical Trial Site 804712
-
Sumy, Ukraine
- Chiesi Clinical Trial Site 804715
-
Vinnytsya, Ukraine
- Chiesi Clinical Trial Site 804703
-
Vinnytsya, Ukraine
- Chiesi Clinical Trial Site 804706
-
Vinnytsya, Ukraine
- Chiesi Clinical Trial Site 804707
-
Vinnytsya, Ukraine
- Chiesi Clinical Trial Site 804714
-
Zaporizhzhya, Ukraine
- Chiesi Clinical Trial Site 804704
-
Zhytomyr, Ukraine
- Chiesi Clinical Trial Site 804708
-
-
-
-
-
Llanelli, United Kingdom
- Chiesi Clinical Trial Site 826702
-
London, United Kingdom
- Chiesi Clinical Trial Site 826703
-
Manchester, United Kingdom
- Chiesi Clinical Trial Site 826704
-
Soham, United Kingdom
- Chiesi Clinical Trial Site 826701
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of asthma ≥ 1 year and diagnosed before 40 years old
- Uncontrolled asthma with double therapy only on high doses of Inhaled CorticoSteroid (ICS) in combination with Long-Acting Beta2 Agonist (LABA) with ACQ-7 (Asthma Control Questionnaire) ≥1.5
- Pre-bronchodilator FEV1 <80% of the predicted normal value
- Positive reversibility test
- At least 1 documented asthma exacerbation in the previous year
Exclusion Criteria:
- Pregnant or lactating women
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
- Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks prior screening
- Current smoker or ex-smoker (>= 10 packs year)
- Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks prior screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CHF 5993 200/6/12.5 µg
Treatment A: CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB |
|
Active Comparator: CHF 1535 200/6 µg
Treatment B: CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF |
|
Active Comparator: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Treatment C (open-label arm): CHF 1535 200/6 µg: 2 inhalations bid + Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction of moderate and severe asthma exacerbations rate
Time Frame: Week 0 to Week 52
|
Week 0 to Week 52
|
Pre-dose FEV1 (Forced Expiratory Volume in the first second)
Time Frame: Week 26
|
Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in morning PEF (Peak Expiratory Flow)
Time Frame: Week 0 to Week 26
|
Week 0 to Week 26
|
|
Peak FEV1 (Peak of Forced Expiratory Volume in the first second) within 3 hours post-dose
Time Frame: Week 26
|
Week 26
|
|
Reduction of severe asthma exacerbations rate
Time Frame: Week 0 to week 52
|
Pooled analysis of CCD-05993AB1-03 and CCD-05993AB2-02 trials
|
Week 0 to week 52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events and Adverse Drug reactions
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Collection of Health Economics outcomes
Time Frame: Week 0 to Week 52
|
Total use of healthcare resources and absence from work
|
Week 0 to Week 52
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Georgio Walter Canonica, MD, University of Medicine, Genoa, Italy
Publications and helpful links
General Publications
- Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30.
- Orlovic M, Magni T, Lukyanov V, Guerra I, Madoni A. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England. Respir Med. 2022 Sep;201:106934. doi: 10.1016/j.rmed.2022.106934. Epub 2022 Jul 19.
- Papi A, Singh D, Virchow JC, Canonica GW, Vele A, Georges G. Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER. Clin Transl Allergy. 2022 Apr 17;12(4):e12145. doi: 10.1002/clt2.12145. eCollection 2022 Apr.
- Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res. 2020 Oct 29;21(1):285. doi: 10.1186/s12931-020-01558-y.
- Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur Respir J. 2020 Sep 24;56(3):2000476. doi: 10.1183/13993003.00476-2020. Print 2020 Sep. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Tiotropium Bromide
Other Study ID Numbers
- CCD-05993AB2-02
- 2015-000717-40 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.
Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarRecruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Universita di VeronaCompleted
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on CHF 5993 200/6/12.5 µg
-
Chiesi Farmaceutici S.p.A.Completed
-
Chiesi Farmaceutici S.p.A.Completed
-
Chiesi Farmaceutici S.p.A.Completed
-
Chiesi Farmaceutici S.p.A.SGS S.A.Recruiting
-
Chiesi Farmaceutici S.p.A.CompletedCOPD (Chronic Obstructive Pulmonary Disease)China, Korea, Republic of, Taiwan
-
Chiesi Farmaceutici S.p.A.Completed
-
Chiesi Farmaceutici S.p.A.Recruiting
-
Chiesi Farmaceutici S.p.A.Completed
-
INSYS Therapeutics IncWithdrawn
-
Chiesi Farmaceutici S.p.A.CompletedAsthmaBulgaria, Germany, Italy, Netherlands, Poland